Survey of Ophthalmology
Volume 48, Issue 4 , Pages 447-451 , July 2003

Foggy visual field defect

  • Rod Foroozan, MD

      Affiliations

    • Corresponding Author InformationReprint address: Rod Foroozan, MD, Neuro Ophthalmology Service, Wills Eye Hospital, Thomas Jefferson University, 840 Walnut St, Suite 930, Philadelphia, PA, 19107
    • ,
  • Lawrence M. Buono, MD

References 

  1. Biton V, Montouris GD, Ritter F, et al.  A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology. 1999;52:1330–1337
  2. Dodgson SJ, Shank RP, Maryanoff BE. Topiramate as an inhibitor of carbonic anhydrase isozymes. Epilepsia. 2000;41:S35–S39
  3. Gilliam F, Wyllie E. Ictal amaurosis: MRI, EEG, and clinical features. Neurology. 1995;45:1619–1621
  4. Miller NR, Newman NJ. Topical diagnosis of lesions in the visual sensory pathway. In:  Miller NR,  Newman NJ editor. ed 5. Walsh & Hoyt's Clinical Neuro-ophthaomology. Vol 1:Williams & Wilkins; 1998;p. 237–386
  5. Ponjavic V, Andreasson S. Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication. Doc Ophthalmol. 2001;102:63–72
  6. Rhee DJ, Goldberg MJ, Parrish RK. Bilateral angle-closure glaucoma and ciliary body swelling from topiramate. Arch Ophthalmol. 2001;119:1721–1723
  7. Sachdeo RC, Glauser TA, Ritter F, et al.  A double-blind, randomized trial of topiramate in Lennox–Gastaut syndrome. Topiramate YL Study Group. Neurology. 1999;52:1882–1887
  8. Sankar PS, Pasquale LR, Grosskreutz CL. Uveal effusion and secondary angle-closure glaucoma associated with topiramate use. Arch Ophthalmol. 2001;119:1210–1211
  9. Sen HA, O'Halloran HS, Lee WB. Case reports and small case series: topiramate-induced acute myopia and retinal striae. Arch Ophthalmol. 2001;119:775–777
  10. Sharief M, Viteri C, Ben-Menachem E, et al.  Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res. 1996;25:217–224
  11. Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache. 2001;41(Suppl 1):S3–S11
  12. Thompson PJ, Baxendale SA, Duncan JS, Sander JW. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry. 2000;69:636–641
  13. White HS, Brown SD, Woodhead JH, et al.  Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res. 1997;28:167–179
  14. Wilton LV, Stephens MD, Mann RD. Visual field defect associated with vigabatrin: observational cohort study. BMJ. 1999;319:1165–1166

☆ This work was supported in part by an unrestricted grant from the Research to Prevent Blindness, Inc., New York, NY.The authors have no proprietary interest in any contents within this manuscript. Dr. Foroozan is supported by the Heed Ophthalmic Foundation, Cleveland, Ohio.

PII: S0039-6257(03)00051-1

doi: 10.1016/S0039-6257(03)00051-1

Survey of Ophthalmology
Volume 48, Issue 4 , Pages 447-451 , July 2003

Article Tools

* Image Usage & Resolution